Jimenez and colleagues5 performed AAV gene therapy to achieve sustaining liver‐specific FGF21 expression in vivo, which ultimately ameliorates obesity and insulin resistance. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.